

Chandrasekar Gopalakrishnan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8341575/publications.pdf>

Version: 2024-02-01

26
papers

725
citations

759233

12
h-index

552781

26
g-index

27
all docs

27
docs citations

27
times ranked

1067
citing authors

#	ARTICLE	IF	CITATIONS
1	Antidepressant Use Late in Pregnancy and Risk of Persistent Pulmonary Hypertension of the Newborn. JAMA - Journal of the American Medical Association, 2015, 313, 2142.	7.4	198
2	Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride. Diabetes Care, 2019, 42, 2204-2210.	8.6	81
3	Effect of a Remotely Delivered Tailored Multicomponent Approach to Enhance Medication Taking for Patients With Hyperlipidemia, Hypertension, and Diabetes. JAMA Internal Medicine, 2018, 178, 1182.	5.1	71
4	Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records. Diabetes, Obesity and Metabolism, 2018, 20, 974-984.	4.4	63
5	Association of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection. JAMA Internal Medicine, 2020, 180, 1596.	5.1	48
6	Brief Report: Patterns and Secular Trends in Use of Immunomodulatory Agents During Pregnancy in Women With Rheumatic Conditions. Arthritis and Rheumatology, 2016, 68, 1183-1189.	5.6	27
7	Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study. Diabetes, Obesity and Metabolism, 2016, 18, 755-765.	4.4	26
8	The relative benefits of claims and electronic health record data for predicting medication adherence trajectory. American Heart Journal, 2018, 197, 153-162.	2.7	26
9	Rationale and design of the Study of a Tele-pharmacy Intervention for Chronic diseases to Improve Treatment adherence (STIC2IT): A cluster-randomized pragmatic trial. American Heart Journal, 2016, 180, 90-97.	2.7	24
10	Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review. Arthritis Care and Research, 2016, 68, 1078-1088.	3.4	24
11	Metformin use and risk of lactic acidosis in people with diabetes with and without renal impairment: a cohort study in Denmark and the UK. Diabetic Medicine, 2017, 34, 485-489.	2.3	19
12	Prevalence and Impact of Having Multiple Barriers to Medication Adherence in Nonadherent Patients With Poorly Controlled Cardiometabolic Disease. American Journal of Cardiology, 2020, 125, 376-382.	1.6	16
13	Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2022, 327, 1051.	7.4	14
14	Safety and Effectiveness of Dabigatran and Other Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation. Clinical Pharmacology and Therapeutics, 2020, 107, 1405-1419.	4.7	12
15	Claims Data Studies of Direct Oral Anticoagulants Can Achieve Balance in Important Clinical Parameters Only Observable in Electronic Health Records. Clinical Pharmacology and Therapeutics, 2019, 105, 979-993.	4.7	11
16	Comparison of a new 3-item self-reported measure of adherence to medication with pharmacy claims data in patients with cardiometabolic disease. American Heart Journal, 2020, 228, 36-43.	2.7	11
17	Evaluation of Socioeconomic Status Indicators for Confounding Adjustment in Observational Studies of Medication Use. Clinical Pharmacology and Therapeutics, 2019, 105, 1513-1521.	4.7	10
18	Evaluating utilization patterns of oral anticoagulants in routine care. Journal of Thrombosis and Haemostasis, 2019, 17, 1033-1043.	3.8	10

#	ARTICLE	IF	CITATIONS
19	Sequential Monitoring of the Comparative Effectiveness and Safety of Dabigatran in Routine Care. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005173.	2.2	8
20	Preferential prescribing and utilization trends of diabetes medications among patients with renal impairment: Emerging role of linagliptin and other dipeptidyl peptidase 4 inhibitors. Endocrinology, Diabetes and Metabolism, 2018, 1, e00005.	2.4	7
21	Time to end the misuse of race in medicine: cases from nephrology. BMJ, The, 2021, 375, n2435.	6.0	6
22	Comparison of measures of medication adherence from pharmacy dispensing and insurer claims data. Health Services Research, 2021, , .	2.0	5
23	Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care. Diabetes, Obesity and Metabolism, 2019, 21, 1824-1836.	4.4	4
24	Comparative Outcomes of Treatment Initiation With Brand vs. Generic Warfarin in Older Patients. Clinical Pharmacology and Therapeutics, 2020, 107, 1334-1342.	4.7	2
25	Development of a Medicare Claims-Based Model to Predict Persistent High-Dose Opioid Use After Total Knee Replacement. Arthritis Care and Research, 2022, 74, 1342-1348.	3.4	1
26	Abstract 17137: Safety and Effectiveness of Dabigatran Relative to Warfarin in Routine Clinical Practice - New Interim Results of Long-term Study Program. Circulation, 2015, 132, .	1.6	1